Medtronic Reported (EV ICD) Study Results of Extravascular ICD System for the Treatment of Arrhythmias
Shots:
- The (EV ICD) study evaluated the EV ICD system in 356 patients with arrhythmias who are at risk of sudden cardiac death at 46 sites in 17 countries in North America, the EU, the Middle East, Asia, Australia & New Zealand
- The results meet its safety & efficacy EPs i.e., patients achieved a defibrillation success rate of 98.7% over historical transvenous ICD studies, and all discrete spontaneous arrhythmias were treated (100%). At 6mos., 92.6% were free from the major system, no major intraprocedural complications & no complications related to the EV ICD procedure or system were observed. The results were presented at ESC 2022 & published in the NEJM
- Additionally, 29 patients experienced inappropriate shocks (9.7%) with a follow-up of 10.6mos.
Ref: PRNewswire | Image: Medtronic
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
